
    
      This is an international, randomized, double-blind, placebo-controlled, Phase II/III trial of
      intravenous recombinant relaxin for the treatment of signs and symptoms in patients
      hospitalized for acute decompensated heart failure. The Phase II pilot study has completed;
      the Phase III main portion of the trial is ongoing.
    
  